GlassScriptPhysician profile
Julia Tinik
NPI 1356817399
$16,005.50
in general payments reported to CMS, 2019-2025
44 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,764 · 2022: $3,922 · 2023: $3,849 · 2024: $3,157 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,319.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,643.60 | 2021-2025 | |
| Novo Nordisk INC | $2,383.37 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,684.56 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,128.76 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $897.74 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $811.02 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $716.61 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $698.73 | 2021-2025 | |
| Amgen INC. | $581.30 | 2021-2025 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $544.43 | 2021-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Mylan Specialty L.P. | $432.02 | 2021-2023 | Yupelri |
| Tactile Systems Technology INC | $354.27 | 2021-2024 | Entre Plus, Flexitouch Plus |
| Exact Sciences Corporation | $345.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $341.62 | 2021-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $337.10 | 2021-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $307.42 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $253.68 | 2021-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $169.74 | 2023-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $150.64 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $134.21 | 2023-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $127.19 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $126.11 | 2022-2024 | |
| Lundbeck LLC | $106.34 | 2022-2025 | Rexulti |
| Cequr Corporation | $85.52 | 2023-2025 | Cequr Simplicity |
| Biohaven Pharmaceutical Holding Company LTD. | $72.65 | 2022 | |
| Amarin Pharma, INC. | $66.15 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $52.13 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $51.62 | 2022-2025 | Spravato |
| Sanofi Pasteur INC. | $48.68 | 2023-2024 | |
| Almatica Pharma LLC | $40.83 | 2022 | |
| Genentech USA, INC. | $36.27 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $32.25 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $31.73 | 2021 | |
| Philips North America LLC | $30.14 | 2022 | |
| Esperion Therapeutics, INC. | $28.12 | 2021-2024 | Nexletol |
| Optinose US, INC. | $24.70 | 2022 | |
| Inspire Medical Systems, INC. | $22.37 | 2024 | Inspire |
| Ibsa Pharma INC. | $20.51 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.53 | 2022 | |
| Intra-Sana Laboratories | $16.22 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Sanofi-Aventis U.S. LLC | $15.77 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2023 | Seglentis, Livalo |
| Eisai INC. | $12.08 | 2021 | |
| Edwards Lifesciences Corporation | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Tinik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.